SCHEMBL3534644

SCHEMBL3534644

Clc1ccc2c(-c3nc4ccccc4[nH]3)n[nH]c2c1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 3/20 0.71
FLT1 P17948 2/20 0.71
CHEK1 O14757 10/20 0.65
CDK2 P24941 11/20 0.62
CDK4 P11802 10/20 0.62
CCNA2 P20248 10/20 0.62
CCND1 P24385 10/20 0.62
CCND3 P30281 10/20 0.62
JAK2 O60674 5/20 0.62
TYK2 P29597 5/20 0.62
JAK3 P52333 5/20 0.62
JAK1 P23458 4/20 0.62
PDPK1 O15530 2/20 0.60
KDR P35968 5/20 0.59
ITK Q08881 2/20 0.56
CDK1 P06493 2/20 0.55
PLK4 O00444 1/20 0.53
AURKA O14965 1/20 0.53
CHUK O15111 1/20 0.53
ROCK2 O75116 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3541234 0.89 ITK (0.71) FGFR1FLT1CHEK1CDK2CDK4
SCHEMBL3531870 0.89 PDPK1 (0.71) FGFR1FLT1CHEK1CDK2CDK4
SCHEMBL3532060 0.84 CHEK1 (0.79) FGFR1FLT1CHEK1CDK2CDK4
SCHEMBL311148 0.84 FGFR1 (1.00) FGFR1FLT1CHEK1CDK2CDK4
SCHEMBL29714859 0.84 FGFR1 (1.00) FGFR1FLT1CHEK1CDK2CDK4
SCHEMBL3543632 0.83 FGFR1 (0.71) FGFR1FLT1CHEK1CDK2CDK4
SCHEMBL3537031 0.83 FGFR1 (0.71) FGFR1FLT1CHEK1CDK2CDK4
SCHEMBL3537487 0.83 ITK (0.80) FGFR1FLT1CHEK1CDK2CDK4
SCHEMBL3533781 0.83 FGFR1 (0.71) FGFR1FLT1CHEK1CDK2CDK4
SCHEMBL3538139 0.83 ALDH1A1 (0.57) FGFR1FLT1CHEK1CDK2CDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7642278-B2 Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2010-01-05 US disclosed
US-7064215-B2 Indazole benzimidazole compounds CHIRON CORPORATION (US) 2006-06-20 US disclosed
US-20060079564-A1 Indazole benzimidazole compounds CHIRON CORPORATION 2006-04-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060079564-A1 Indazole benzimidazole compounds ABL1, ABL2, ALK FGFR1 886/4885FLT1 2793/4885CHEK1 798/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.